Show simple item record

FieldValueLanguage
dc.contributor.authorZheng, Collin Yarmeng
dc.date.accessioned2026-06-02T03:09:08Z
dc.date.available2026-06-02T03:09:08Z
dc.date.issued2026en_AU
dc.identifier.urihttps://hdl.handle.net/2123/35382
dc.description.abstractImmune checkpoint blockades have transformed oncology, yet a persistent clinical puzzle remains: Why do some patients exhibit delayed responses, with tumours that initially grow or plateau before abruptly regressing? This thesis tackles that question with a multi-scale mathematical study that couples analytically tractable ordinary differential equation (ODE) models with a spatial, stochastic agent-based model (ABM). In ODE form, we show that delayed responses can arise intrinsically, without imposed time lags, via costimulation bottlenecks and slow passages near tipping points associated with special saddle-node bifurcations. We map delayed responses to a statistically-thin part of the model parameter space, suggesting their rarity. Our ODE results enable us to propose an immune profile framework that maps patient prognosis to the natural strength of their immune system---an idea that has become increasingly popular in clinical research since COVID-19. To move beyond mean-field assumptions, we develop an ABM tracking cancer cells, dendritic cells (DCs), CD8+ T cells, and Tregs at single-cell resolution, with molecular attributes and cell-level rules. Mechanistically, our ABM explains why combination therapy outperforms monotherapy: anti-CTLA-4 'reopens the gate' while anti-PD-1 'lifts the brake', yielding a larger and fitter effector CD8+ T cell pool. Our results supports two hypothesised mechanisms of action underlying CTLA-4 blockades---Treg depletion in humans and Treg-driven stripping of B7 ligands---highlighting how depleting suppressors and protecting strategically-important ligands reopen the costimulatory pathway. We characterise delayed responses as an alignment of a multitude of immune events, followed by a fast cascade of killing. This suggests that DC therapies prioritising net DC recruitment and T cell therapies that prioritise tumour-infiltrating lymphocyte (TIL) survivability synergise well with immune checkpoint blockades.en_AU
dc.language.isoenen_AU
dc.subjectimmunotherapyen_AU
dc.subjectcheckpointsen_AU
dc.subjectCTLA4en_AU
dc.subjectPD1en_AU
dc.subjectPDL1en_AU
dc.subjectmodellingen_AU
dc.subjectODEen_AU
dc.subjectABMen_AU
dc.subjectbifurcationen_AU
dc.subjectcostimulationen_AU
dc.titleMathematical Models for Immune Checkpoint Blockade and Delayed Responsesen_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en
usyd.facultySeS faculties schools::Faculty of Science::School of Mathematics and Statisticsen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorKim, Peter Sehoon


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.